论文部分内容阅读
目的分析参麦注射液辅助治疗慢性充血性心力衰竭的临床疗效及安全性。方法选取2013年2月至2014年2月于我院就诊的慢性充血性心力衰竭患者100例,将其随机分为两组,每组各50例,对照组予心衰标准治疗,即口服利尿剂、血管扩张剂、强心剂等药物,实验组在对照组治疗的基础上静脉滴注参麦注射液,比较两种治疗方法的临床疗效、血流动力学指标变化、NT-pro BNP含量变化及六分钟步行距离。结果实验组总有效率为95.0%,对照组总有效率为80.0%,组间比较具有统计学差异(P<0.05)。结论参麦注射液辅助治疗慢性充血性心力衰竭疗效显著,值得临床进一步推广。
Objective To analyze the clinical efficacy and safety of Shenmai injection in the treatment of chronic congestive heart failure. Methods 100 patients with chronic congestive heart failure treated in our hospital from February 2013 to February 2014 were randomly divided into two groups with 50 cases in each group. The control group was given standard treatment of heart failure, ie oral diuretic Agent, vasodilator, tonicity and other drugs. The experimental group was given intravenous infusion of Shenmai injection on the basis of the control group, and compared the clinical curative effect, hemodynamic indexes and the content of NT-pro BNP Six minutes walking distance. Results The total effective rate was 95.0% in the experimental group and 80.0% in the control group, with statistical significance (P <0.05). Conclusion Shenmai injection in the treatment of chronic congestive heart failure significant effect, it is worth further clinical promotion.